Literature DB >> 19293268

Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes.

Jérôme Bertherat1, Anélia Horvath, Lionel Groussin, Sophie Grabar, Sosipatros Boikos, Laure Cazabat, Rosella Libe, Fernande René-Corail, Sotirios Stergiopoulos, Isabelle Bourdeau, Thalia Bei, Eric Clauser, Alain Calender, Lawrence S Kirschner, Xavier Bertagna, J Aidan Carney, Constantine A Stratakis.   

Abstract

BACKGROUND: The "complex of myxomas, spotty skin pigmentation, and endocrine overactivity," or "Carney complex" (CNC), is caused by inactivating mutations of the regulatory subunit type 1A of the cAMP-dependent protein kinase (PRKAR1A) gene and as yet unknown defect(s) in other gene(s). Delineation of a genotype-phenotype correlation for CNC patients is essential for understanding PRKAR1A function and providing counseling and preventive care.
METHODS: A transatlantic consortium studied the molecular genotype and clinical phenotype of 353 patients (221 females and 132 males, age 34 +/- 19 yr) who carried a germline PRKAR1A mutation or were diagnosed with CNC and/or primary pigmented nodular adrenocortical disease.
RESULTS: A total of 258 patients (73%) carried 80 different PRKAR1A mutations; 114 (62%) of the index cases had a PRKAR1A mutation. Most PRKAR1A mutations (82%) led to lack of detectable mutant protein (nonexpressed mutations) because of nonsense mRNA mediated decay. Patients with a PRKAR1A mutation were more likely to have pigmented skin lesions, myxomas, and thyroid and gonadal tumors; they also presented earlier with these tumors. Primary pigmented nodular adrenocortical disease occurred earlier, was more frequent in females, and was the only manifestation of CNC with a gender predilection. Mutations located in exons were more often associated with acromegaly, myxomas, lentigines, and schwannomas, whereas the frequent c.491-492delTG mutation was commonly associated with lentigines, cardiac myxomas, and thyroid tumors. Overall, nonexpressed PRKAR1A mutations were associated with less severe disease.
CONCLUSION: CNC is genetically and clinically heterogeneous. Certain tumors are more frequent, with specific mutations providing some genotype-phenotype correlation for PRKAR1A mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19293268      PMCID: PMC2690418          DOI: 10.1210/jc.2008-2333

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Editorial: Carney complex--clarity and complexity.

Authors:  C D Malchoff
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

Review 2.  Carney complex: the first 20 years.

Authors:  Sosipatros A Boikos; Constantine A Stratakis
Journal:  Curr Opin Oncol       Date:  2007-01       Impact factor: 3.645

3.  Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia.

Authors:  Anelia Horvath; Veronica Mericq; Constantine A Stratakis
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

4.  Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population.

Authors:  Anelia Horvath; Christoforos Giatzakis; Audrey Robinson-White; Sosipatros Boikos; Elizabeth Levine; Kurt Griffin; Erica Stein; Virginia Kamvissi; Payal Soni; Ioannis Bossis; Wouter de Herder; J Aidan Carney; Jérôme Bertherat; Peter K Gregersen; Elaine F Remmers; Constantine A Stratakis
Journal:  Cancer Res       Date:  2006-12-15       Impact factor: 12.701

5.  Protein kinase A effects of an expressed PRKAR1A mutation associated with aggressive tumors.

Authors:  Elise Meoli; Ioannis Bossis; Laure Cazabat; Manos Mavrakis; Anelia Horvath; Sotiris Stergiopoulos; Miriam L Shiferaw; Glawdys Fumey; Karine Perlemoine; Michael Muchow; Audrey Robinson-White; Frank Weinberg; Maria Nesterova; Yianna Patronas; Lionel Groussin; Jérôme Bertherat; Constantine A Stratakis
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex.

Authors:  L S Kirschner; J A Carney; S D Pack; S E Taymans; C Giatzakis; Y S Cho; Y S Cho-Chung; C A Stratakis
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex.

Authors:  L S Kirschner; F Sandrini; J Monbo; J P Lin; J A Carney; C A Stratakis
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

8.  Male infertility as a component of Carney complex.

Authors:  P Wieacker; C A Stratakis; A Horvath; S Klose; I Nickel; P Buhtz; P Muschke
Journal:  Andrologia       Date:  2007-10       Impact factor: 2.775

9.  Large deletions of the PRKAR1A gene in Carney complex.

Authors:  Anelia Horvath; Ioannis Bossis; Christoforos Giatzakis; Elizabeth Levine; Frank Weinberg; Elise Meoli; Audrey Robinson-White; Jennifer Siegel; Payal Soni; Lionel Groussin; Ludmila Matyakhina; Somya Verma; Elaine Remmers; Maria Nesterova; J Aidan Carney; Jérôme Bertherat; Constantine A Stratakis
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay.

Authors:  Elizabeth L Greene; Anelia D Horvath; Maria Nesterova; Christoforos Giatzakis; Ioannis Bossis; Constantine A Stratakis
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

View more
  132 in total

Review 1.  PRKAR1A and the evolution of pituitary tumors.

Authors:  Lawrence S Kirschner
Journal:  Mol Cell Endocrinol       Date:  2010-05-06       Impact factor: 4.102

Review 2.  Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment.

Authors:  Isaac Levy; Anelia Horvath; Monalisa Azevedo; Rodrigo Bertollo de Alexandre; Constantine A Stratakis
Journal:  Curr Opin Pharmacol       Date:  2011-10-31       Impact factor: 5.547

3.  The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.

Authors:  C A Stratakis; M A Tichomirowa; S Boikos; M F Azevedo; M Lodish; M Martari; S Verma; A F Daly; M Raygada; M F Keil; J Papademetriou; L Drori-Herishanu; A Horvath; K M Tsang; M Nesterova; S Franklin; J-F Vanbellinghen; V Bours; R Salvatori; A Beckers
Journal:  Clin Genet       Date:  2010-11       Impact factor: 4.438

4.  A novel splice site mutation of the PRKAR1A gene, C.440+5 G>C, in a Chinese family with Carney complex.

Authors:  J Fu; F Lai; Y Chen; X Wan; G Wei; Y Li; H Xiao; X Cao
Journal:  J Endocrinol Invest       Date:  2018-01-09       Impact factor: 4.256

5.  Organ-sparing surgery for large cell calcifying Sertoli cell tumour in a patient with Carney complex.

Authors:  Maria José Freire; Pedro Nunes; Luà S Sousa; Arnaldo Figueiredo
Journal:  BMJ Case Rep       Date:  2017-07-14

Review 6.  Acromegaly in Carney complex.

Authors:  T Cuny; T T Mac; P Romanet; H Dufour; I Morange; F Albarel; A Lagarde; F Castinetti; T Graillon; M O North; A Barlier; T Brue
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 7.  Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics.

Authors:  Paraskevi Salpea; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-09-05       Impact factor: 4.102

Review 8.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

9.  PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.

Authors:  Zakariae Bram; Estelle Louiset; Bruno Ragazzon; Sylvie Renouf; Julien Wils; Céline Duparc; Isabelle Boutelet; Marthe Rizk-Rabin; Rossella Libé; Jacques Young; Dennis Carson; Marie-Christine Vantyghem; Eva Szarek; Antoine Martinez; Constantine A Stratakis; Jérôme Bertherat; Hervé Lefebvre
Journal:  JCI Insight       Date:  2016-09-22

10.  Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome.

Authors:  Johannes Hofland; Wouter W de Herder; Lieke Derks; Leo J Hofland; Peter M van Koetsveld; Ronald R de Krijger; Francien H van Nederveen; Anelia Horvath; Constantine A Stratakis; Frank H de Jong; Richard A Feelders
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.